CANCER THERAPEUTICS INC Financials

PERIOD ENDING31-Aug-0931-May-0928-Feb-0930-Nov-08Total Revenue -   -   -   -  Cost of Revenue -   -   -   -  Gross Profit -   -   -   -  Operating ExpensesResearch Development -   -   -   -  Selling General and Administrative132  155  0  10  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(132)(155)(0)(10)Income from Continuing OperationsTotal Other Income/Expenses Net(1)(1) -   -  Earnings Before Interest And Taxes(133)(156)(0)(10)Interest Expense1  15  5  6  Income Before Tax(134)(171)(6)(15)Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(134)(171)(6)(15)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   ...
Click here to read the whole Article (external link)

CANCER THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION You should read the following discussion of the company's financial condition and results of operations in conjunction with the audited financial statements and related notes included in the filing of the company's latest annual 10-K. This discussion may contain forward-looking statements, including, without limitation, statements regarding our expectations, beliefs, intentions, or future strategies that are signified by the words "expects," "anticipates," "intends," "believes," or similar language. Actual results could differ materially from those projected in the forward looking statements. You should carefully consider the information under the caption "Risk Factors" in this filing, in addition to the other information set forth in this report. We caution you that Cancer Therapeutics' business and financial performance is subject to substantial risks and uncertainties. Overview On July 31, 2007, the Company sold all operating assets to a shareholder of the Company. This transaction resulted in the Company becoming a shell (as defined in Rule 12b-2 of the Exchange Act). Results of Operations Following is our discussion of the relevant items affecting results of operations for the periods ended August 31, 2009 and 2008. The operations of the Company are continually decreasing as it has entered into shell status. Revenues. Cancer Therapeutics generated zero net revenues during the three months ended August 31, 2009 and 2008. As the Company has entered into shell status, revenues are expected to be at or near zero for the foreseeable future. Consulting Expense. Consulting expense for the three months ended August 31, 2009 was $106,844 compared to $-0- for the three months ended August 31, 2008. The Company issued 40,000,000 shares of common stock to various consulting firms on April 15, 2009 as we seek potential acquisitions and ...
Click here to read the whole Article (external link)

Cancer Therapeutics Announces Letter of Intent With NanoTherapies, LLC

SALT LAKE CITY, UT--(Marketwire - 10/16/09) - Cancer Therapeutics, Inc. (OTC.BB:CTHP - News), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies. Terms of the agreement, which include six million restricted shares to NanoTherapies, are subject to formal approval by the Managing Member and Governing Board of Directors of NanoTherapies, LLC. In addition, a full audit of NanoTherapies needs to be completed as well for a binding agreement. Recently, Cancer Therapeutics announced the completion of a 25 percent stake in NanoTherapies, making it the company's first acquisition. Chene Gardner, President and CEO of Cancer Therapeutics, said he anticipates finalizing the new agreement to come within the next 90 days.NanoTherapies develops life-changing therapies for cancer treatment based on an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications.About Cancer Therapeutics, Inc.:Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result...
Click here to read the whole Article (external link)

Cancer Therapeutics Names Dr. Mark Kester to Advisory Board

SALT LAKE CITY, UT--(Marketwire - 09/30/09) - Cancer Therapeutics, Inc. (OTC.BB:CTHP - News), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has named Dr. Mark Kester to its Advisory Board. Dr. Kester is the G. Thomas Passananti Professor of Pharmacology at Penn State Hershey College of Medicine. He becomes the latest member of the company's board and joins Caroline V. Corner, PhD. "Dr. Kester will be a vital part of our newly formed board due to his exceptional expertise with nanotechnology as well as his creation and development of innovative medical techniques," said Chene Gardner, President and CEO of Cancer Therapeutics, Inc. "Dr. Kester's combined experience as a doctor, author, researcher and businessman are ideally suited for this role. We are anxious to get him involved with the ongoing development of our company."Before accepting his prestigious endowed professorship, he was a Distinguished Professor of Pharmacology as well as Interim Chair of Pharmacology. Dr. Kester's research interests include the design, characterization and validation of nanotechnologies for targeted drug delivery. His laboratory has evaluated nanoliposomes, nanodendrimers and nanocolloids as effective drug delivery vehicles for pharmacological and molecular agents. Recent work focuses on nontoxic nanoscale systemic delivery systems for hydrophobic pro-apoptotic lipids as well as siRNAs that target mutated tumorigenic proteins.Dr. Kester's ...
Click here to read the whole Article (external link)

CANCER THERAPEUTICS INC Files SEC form 10-K, Annual Report

Show all filings for CANCER THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 10-K for CANCER THERAPEUTICS INC 15-Sep-2009Annual Report Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended fo...
Click here to read the whole Article (external link)

Cancer Therapeutics Retains Capital Group Communications for Its Public Relations

SALT LAKE CITY, UT--(Marketwire - 08/06/09) - Cancer Therapeutics, Inc. (OTC.BB:CTHP - News), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today the company has retained San Francisco-based Capital Group Communications, Inc. for its public relations efforts. Capital Group Communications, Inc. ("CGC") specializes in providing brokers, fund managers and institutions with world class investor relations for dynamic growth companies. CGC and its staff of highly respected industry leaders have over 185 combined years of finance, investor relations and Media experience. CGC believes investor relations is a highly specialized business discipline that requires expert financial and public relations knowledge. The company's due diligence employs the same criteria as major investment banking firms. Communicating effectively with the capital markets requires creativity, discipline, an understanding of legal and accounting issues and most importantly, daily interaction with the Street. Part of CGC's philosophy is that to be effective, marketing and media relations need to be in sync with broader fundamental strategic goals that support growing shareholder value.About Cancer Therapeutics, Inc.:Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end res...
Click here to read the whole Article (external link)

Cancer Therapeutics Names Savvy Financial Expert and Active Investor to Its Newly Formed Advisory Board

SALT LAKE CITY, UT--(Marketwire - 06/22/09) - Cancer Therapeutics, Inc. (OTC.BB:CTHP - News), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has named R. Paul Gray to its Advisory Board. Mr. Gray is an active early stage investor and strategic consultant to numerous development stage companies. He is an audit committee financial expert as defined under the rules and regulations of the Securities and Exchange Commission (SEC) and meets the financial sophistication requirements of the listing standards of the NASDAQ.Mr. Gray currently is the Managing Member of Core Concepts, LLC, a strategic and financial consulting firm which he founded in 2002. Mr. Gray has been a member of the Board of Directors of United Therapeutics Corporation since 2003 and currently serves as Chairman of their audit committee and member of the compensation committee. He also is Chairman of the Board of several companies in which he has invested. From 1985 to 1999, Mr. Gray practiced as a Certified Public Accountant at Ernst & Young LLP, KPMG LLP and Beers & Cutler LLP. Mr. Gray has served as an Officer and/or Chief Financial Officer for his client's and portfolio companies from time to time."Mr. Gray has a passion to the advancement and development of life-changing and paradigm shifting technologies and has actively invested his time and money to this pursuit and related opportunities; he is a welcomed addition to our Advisory Board," said Chene Ga...
Click here to read the whole Article (external link)

Cancer Therapeutics Announces Formation of Advisory Board

Expired Yahoo - Document Has Expired/iw/090608/0508816.html Options that might be of interest: Go to the Yahoo! home page. Go to the Yahoo! Finance home page. Go to the Yahoo! Loan Center. Go to the Yahoo! Insurance Center. Other resources: Message Boards - Stock Chat - Finance Clubs ...
Click here to read the whole Article (external link)

CANCER THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financi

Show all filings for CANCER THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for CANCER THERAPEUTICS INC 29-May-2009Completion of Acquisition or Disposition of Assets, Other Events, Financi Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informati...
Click here to read the whole Article (external link)